Stockreport

Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]

Tectonic Therapeutic, Inc.  (TECX) 
PDF First subject dosed with TX000045 (“TX45”) in APEX Phase 2 clinical trial in early October, with topline results expected in 2026 Development Candidate TX002100 (“TX2 [Read more]